Subscribe Us

header ads

Recents

header ads

Orphan Drugs Market Size At Around US$ 438.9 Bn In 2030

The orphan drugs market would grow at a CAGR of 12.48% over the predicted time frame. The market is expected to increase in value from US$ 171.31 Bn in 2022 to US$ 438.9 Bn in 2030.

Orphan Drugs Market Size 2022 To 2030

The on orphan drugs Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/2238

A recent report provides crucial insights along with application based and forecast information in the Global Orphan drugs Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Orphan drugs market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Orphan drugs market are included as given below:

Orphan drugs Market Key Players are: F. Hoffmann-La Roche Ltd, Celgene Corporation, Merk & Co., Inc., Novartis AG, Sanofi, Takeda Pharmaceutical Company Limited, AstraZeneca, Alexion Pharmaceuticals Inc., Eli Lilly and Company, and Amgen Inc.

Market Segments

By Drug Type

  • Biologicals
  • Non-Biologicals

By Therapy

  • Oncology
    • Ovarian cancer
    • Multiple Myeloma
    • Pancreatic Cancer
    • Renal Cell Carcinoma
    • Others
  • Haematology
    • Hereditary Angioedema
    • Hemophilia
    • Others
  • Neurology
    • Alzheimer’s Disease
    • Huntington’s Disease
    • Duchenne Muscular Dystrophy
    • Others
  • Infectious Diseases
  • Metabolic Disorders
    • Gaucher Disease
    • Hypoparathyroidism
    • Hunter Syndrome
    • Fabry Disease
    • Others
  • Endocrinology
  • Immunology
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others 

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Report Objectives

  • To define, describe, and forecast the global orphan drugs market based on product, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
  • To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
  • To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the orphan drugs market

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Orphan Drugs Market 

5.1. COVID-19 Landscape: Orphan Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Orphan Drugs Market, By Drug Type

8.1. Orphan Drugs Market, by Drug Type, 2022-2030

8.1.1 Biologicals

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Non-Biologicals

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Orphan Drugs Market, By Therapy

9.1. Orphan Drugs Market, by Therapy, 2022-2030

9.1.1. Oncology

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Haematology

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Neurology

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Infectious Diseases

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Metabolic Disorders

9.1.5.1. Market Revenue and Forecast (2017-2030)

9.1.6. Endocrinology

9.1.6.1. Market Revenue and Forecast (2017-2030)

9.1.7. Immunology

9.1.7.1. Market Revenue and Forecast (2017-2030)

9.1.8. Others

9.1.8.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Orphan Drugs Market, By Distribution Channel 

10.1. Orphan Drugs Market, by Distribution Channel, 2022-2030

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Orphan Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.1.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.1.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.2.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.2.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.3.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.3.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.4.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.5.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Therapy (2017-2030)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 12. Company Profiles

12.1. F. Hoffmann-La Roche Ltd

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Celgene Corporation

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Merk & Co., Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Novartis AG

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Sanofi

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Takeda Pharmaceutical Company Limited

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. AstraZeneca

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Alexion Pharmaceuticals Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Eli Lilly and Company

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Amgen Inc

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

13.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

Post a Comment

0 Comments